<DOC>
	<DOC>NCT00545389</DOC>
	<brief_summary>Evaluate the percentage of subjects in remission at the end of an 8-week treatment period for three dose groups (SPD476 1.2 g/day, 2.4 g/day or 4.8 g/day, administered once daily).</brief_summary>
	<brief_title>Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>male &amp; female subjects greater than or equal to 18 years of age with newly diagnosed or relapsing mild to moderate ulcerative colitis general medical assessment satisfactory and no clinically significant and relevant abnormalities severe ulcerative colitis subject in relapse for &gt; 6 weeks use of systemic or rectal steroids within last 4 weeks prior to baseline subjects with proctitis, previous colonic surgery, Crohn's disease, bleeding disorders, active ulcer disease subjects hypersensitive to salicylates/aspirin subjects with moderate or severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>